(Date:9/5/2008)...FRANKLIN, Mass., Sept. 5 /PRNewswire/ -- Arthrosur...eveloper of less-invasive joint,resurfacing system...e U.S.,FDA to begin its pivotal investigation for ...DA stated that "there are no outstanding safety,co...iation., Arthrosurface has been evaluating the sa...
(Date:9/5/2008)...The National Institute of Diabetes and Digestive a...nstitutes of Health (NIH), announces awards to eig...ive studies of urologic chronic pelvic pain disord...rostate. The total research investment for the fiv...ion. , "The launch of this novel research effort...
(Date:9/5/2008)...MIDLOTHIAN, Va., Sept. 5 /PRNewswire/ -- On Saturd...e featured on the Oxygen Network show Today,s,Fami...is highlighted as a,leading medical device company...ith effective nebulizers and compressors that deli...ur vision is to improve the lives of those affecte...
(Date:9/5/2008)...ATLANTA, Sept. 5 /PRNewswire/ -- EthicAd, a nonpro...h through consumer education, announces,the launch... public better,understand direct-to-consumer (DTC)..., "Be Smart About Prescription Drug Advertising," ...and Research and was,developed by the FDA in partn...
Breaking Medicine News(10 mins):Health News:Arthrosurface HemiCAP(R) Focal Knee Resurfacing Implant Receives FDA Approval to Move into Final Investigational Stage 2Health News:NIH launches unique effort to advance study of urologic chronic pelvic pain disorders 2Health News:NIH launches unique effort to advance study of urologic chronic pelvic pain disorders 3Health News:PARI Respiratory Equipment Featured on Oxygen Network 2Health News:Prescription Drug Advertising Subject of New FDA Web Site for Consumers 2...for health, especially the role of fats, had been ...nn State University had found out that the between... it is not possible to have the healthy meal by ba...ne particular kind of fats. The right combination ...
...rough in the advancement of scientific technology,...ic mutation at a fraction of cost. It combines the...agonal gel electrophoresis. The technology devised...of Southampton in collaboration with Bristol, Univ...
...y transmitted diseases, incidence is rising among...ng them. AIDS is now a chronic disease and not a f...creased use of methamphetamines (that enhances s...her dimension of new social behaviour is the use ...
...is likely to reduce the risk of contacting HIV fro...0%. A recent study involved 3,000 HIV negative men...umcised and other half were not circumcised. The...archers found that for every ten uncircumcised men...
Other Medicine News:(Date:9/4/2008)...- 100 mg cohort demonstrates potent antiviral acti... profile -, CAMBRIDGE, Mass., Sept. 4 /PRNew...Nasdaq: IDIX ), a biopharmaceutical company engag...he treatment of human viral,and other infectious d...,proof-of-concept study evaluating IDX899, a non-n...
(Date:9/3/2008)..., NAA says: Wrong Question Asked. Wrong Children ...ept. 3 /PRNewswire-USNewswire/ -- A Centers for Di...today claims there is no link,between the MMR vacc...AA),says this study does nothing to dispel the gro...on and raises several questions concerning design,...
(Date:9/3/2008)... September is National Vascular Disease ...RNewswire/ -- Diffusion Pharmaceuticals,LLC, a cli...ng new drugs,for the treatment of unmet medical ne...atients in a Phase I/II clinical trial of its lead...e trial, designated NCT00725881,on the clinicaltri...
(Date:9/3/2008)... Company to Discuss Phase 3 Plans ...- Agile Therapeutics, Inc.,announced today that i...n,the development of the company,s new, innovative... the company refers to by its internal product,cod...y successfully met its,primary endpoint of ovulati...
Breaking Medicine Technology:Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 2Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 3Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 4CDC Misses Target With Flawed MMR/Autism Study 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Tongue Drive system lets persons with disabilities operate powered wheelchairs computers 22909 1Tongue Drive system lets persons with disabilities operate powered wheelchairs computers 22909 2Tongue Drive system lets persons with disabilities operate powered wheelchairs computers 22909 3Tongue Drive system lets persons with disabilities operate powered wheelchairs computers 22909 4A single mechanism for hypertension insulin resistance and immune suppression 3813 1A single mechanism for hypertension insulin resistance and immune suppression 3813 2A single mechanism for hypertension insulin resistance and immune suppression 3813 3A single mechanism for hypertension insulin resistance and immune suppression 3813 4Heavy birthweight babies twice as likely to develop rheumatoid arthritis 22904 1Activity Linked Heat Illness Needs Prompt Attention 22901 1Activity Linked Heat Illness Needs Prompt Attention 22901 2Activity Linked Heat Illness Needs Prompt Attention 22901 3...3, 2007--A part of the brain first,affected by Alz...www.nia.nih.gov/Alzheimers/">http://www.nia.nih.go...ne for the disorder, a brain,imaging study by rese... (NIMH), one of the National Institutes of Health ...tructure in the lower middle,part of the brains ou...
...USINESS WIRE)--Apr 25, 2007 - DuoCort AB,today ann...mg and,20 mg dual release hydrocortisone tablets f...9th European Congress of Endocrinology on,April 30...harmacokinetics of the new hydrocortisone tablets ...hat both the DuoCort 5 mg and 20 mg,hydrocortisone...
Other Medicine Technology:Cortex Area Thinner in Youth with Alzheimers-Related Gene 2Cortex Area Thinner in Youth with Alzheimers-Related Gene 3Cortex Area Thinner in Youth with Alzheimers-Related Gene 4DuoCort AB: DuoCort announces Phase I Data Presentation at the,European Congress of Endocrinology 2...ries is a national reference laboratory and a worl... development. ARUP offers an extensive test menu o...cal and anatomic pathology. Owned by the Universit... than half of the nation's university teaching hos...
...ries is a national reference laboratory and a worl... development. ARUP offers an extensive test menu o...cal and anatomic pathology. Owned by the Universit... than half of the nation's university teaching hos...
...ries is a national reference laboratory and a worl... development. ARUP offers an extensive test menu o...cal and anatomic pathology. Owned by the Universit... than half of the nation's university teaching hos...
...ries is a national reference laboratory and a worl... development. ARUP offers an extensive test menu o...cal and anatomic pathology. Owned by the Universit... than half of the nation's university teaching hos...
Medicine Products: